{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:37Z","timestamp":1784930737869,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104790","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T14:44:34Z","timestamp":1777214674000},"page":"104790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-1117","authenticated-orcid":false,"given":"Naruto","family":"Taira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kashiwaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tsugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikata","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.breast.2026.104790_bib1","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO Guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104790_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12282-020-01085-0","article-title":"The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition","volume":"27","author":"Shimoi","year":"2020","journal-title":"Breast Cancer"},{"issue":"9","key":"10.1016\/j.breast.2026.104790_bib3","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1111\/cas.15474","article-title":"Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS)","volume":"113","author":"Yamamoto","year":"2022","journal-title":"Cancer Sci"},{"issue":"14","key":"10.1016\/j.breast.2026.104790_bib4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO-24-01673","article-title":"Pertuzumab retreatment for human epidermal growth factor receptor 2-positive locally advanced\/metastatic breast cancer (PRECIOUS Study): final overall survival analysis","volume":"43","author":"Yamamoto","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104790_bib5","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/annonc\/mdw258","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104790_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104790_bib7","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","article-title":"Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer","volume":"24","author":"Cort\u00e9s","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104790_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jjco\/hyy097","volume":"48","author":"Yamamoto","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104790_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104790_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF02966719","article-title":"Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan","volume":"10","author":"Okamoto","year":"2003","journal-title":"Breast Cancer"},{"issue":"16","key":"10.1016\/j.breast.2026.104790_bib11","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","article-title":"Statistical challenges in the analysis of health-related quality of life in cancer clinical trials","volume":"34","author":"Bonnetain","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104790_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.breast.2026.104790_bib13","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"10390","key":"10.1016\/j.breast.2026.104790_bib14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.breast.2026.104790_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:30:05Z","timestamp":1784928605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"alternative-id":["S0960977626001001"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104790","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104790"}}